Apellis Pharmaceuticals Stock Performance
| APLS Stock | USD 34.14 1.51 4.63% |
The firm shows a Beta (market volatility) of 0.67, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apellis Pharmaceuticals is expected to be smaller as well. At this point, Apellis Pharmaceuticals has a negative expected return of -0.14%. Please make sure to confirm Apellis Pharmaceuticals' total risk alpha, as well as the relationship between the skewness and day median price , to decide if Apellis Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 4.63 | Five Day Return 22.89 | Year To Date Return (44.28) | Ten Year Return 143.34 | All Time Return 143.34 |
1 | Disposition of 192 shares by Chopas James George of Apellis Pharmaceuticals at 36.206 subject to Rule 16b-3 | 09/16/2024 |
2 | Acquisition by Dunlop A. Sinclair of 4600 shares of Apellis Pharmaceuticals at 13.19 subject to Rule 16b-3 | 09/24/2024 |
3 | Would Apellis Pharmaceuticals Be Better Off With Less Debt | 10/18/2024 |
4 | Disposition of 182146 shares by Francois Cedric of Apellis Pharmaceuticals subject to Rule 16b-3 | 11/01/2024 |
5 | Editas Medicine Reports Q3 Loss, Misses Revenue Estimates | 11/04/2024 |
6 | Apellis Pharmaceuticals, Inc. Reports Q3 Loss, Lags Revenue Estimates | 11/05/2024 |
7 | Apellis Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Revenue Surge and ... | 11/06/2024 |
8 | Wellington Management Group LLP Reduces Stake in Apellis Pharmaceuticals Inc | 11/08/2024 |
9 | T. Rowe Price Investment Management Reduces Stake in Apellis Pharmaceuticals | 11/14/2024 |
10 | EcoR1 Capital, LLC Adjusts Stake in Centessa Pharmaceuticals PLC | 11/15/2024 |
11 | Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals Inc. | 11/22/2024 |
| Begin Period Cash Flow | 553.1 M |
Apellis |
Apellis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,890 in Apellis Pharmaceuticals on August 30, 2024 and sell it today you would lose (476.00) from holding Apellis Pharmaceuticals or give up 12.24% of portfolio value over 90 days. Apellis Pharmaceuticals is currently does not generate positive expected returns and assumes 3.5144% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Apellis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apellis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apellis Pharmaceuticals, and traders can use it to determine the average amount a Apellis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0407
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | APLS |
Estimated Market Risk
| 3.51 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Apellis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apellis Pharmaceuticals by adding Apellis Pharmaceuticals to a well-diversified portfolio.
Apellis Pharmaceuticals Fundamentals Growth
Apellis Stock prices reflect investors' perceptions of the future prospects and financial health of Apellis Pharmaceuticals, and Apellis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apellis Stock performance.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 4.13 B | ||||
| Shares Outstanding | 124.39 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 17.12 X | ||||
| Price To Sales | 5.94 X | ||||
| Revenue | 396.59 M | ||||
| Gross Profit | 69.79 M | ||||
| EBITDA | (495.21 M) | ||||
| Net Income | (528.63 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 110.93 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 1.94 X | ||||
| Cash Flow From Operations | (594.74 M) | ||||
| Earnings Per Share | (2.03) X | ||||
| Market Capitalization | 4.25 B | ||||
| Total Asset | 788.73 M | ||||
| Retained Earnings | (2.84 B) | ||||
| Working Capital | 518.74 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
About Apellis Pharmaceuticals Performance
Assessing Apellis Pharmaceuticals' fundamental ratios provides investors with valuable insights into Apellis Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Apellis Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 913.04 | 1,521 | |
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (2.72) | (2.85) |
Things to note about Apellis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Apellis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apellis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals Inc. |
- Analyzing Apellis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apellis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Apellis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apellis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apellis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apellis Pharmaceuticals' stock. These opinions can provide insight into Apellis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.